Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

Aerie Pharmaceuticals (NASDAQ: AERI) announced that Vicente Anido, Jr., Ph.D., CEO, will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 12:45 p.m. ET. The presentation will provide an overview and business update of Aerie. A live webcast will be available on Aerie's website, with replays accessible for 10 business days. Aerie focuses on developing innovative therapies for open-angle glaucoma and other ocular diseases, with products like Rhopressa® and Rocklatan® aimed at reducing intraocular pressure.

Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20^th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update.

The fireside discussion will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com. A replay of each fireside discussion will be available for 10 business days.

About Aerie Pharmaceuticals, Inc.

Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases. Aerie’s first product, Rhopressa^® (netarsudil ophthalmic solution) 0.02%, a once-daily eye drop approved by the U.S. Food and Drug Administration (FDA) for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, was launched in the United States in April 2018. In clinical trials of Rhopressa^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rhopressa^®, including the product label, is available at www.rhopressa.com. Aerie’s second product for the reduction of elevated IOP in patients with open-angle glaucoma or ocular hypertension, Rocklatan^® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005%, the first and only fixed-dose combination of Rhopressa^® and the widely-prescribed PGA (prostaglandin analog) latanoprost, was launched in the United States in May 2019. In clinical trials of Rocklatan^®, the most common adverse reactions were conjunctival hyperemia, corneal verticillata, instillation site pain, and conjunctival hemorrhage. More information about Rocklatan^®, including the product label, is available at www.rocklatan.com. Aerie continues to focus on global expansion and the development of additional product candidates and technologies in ophthalmology, including for wet age-related macular degeneration and diabetic macular edema. More information is available at www.aeriepharma.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005049/en/

FAQ

When is Aerie Pharmaceuticals presenting at the Needham Virtual Healthcare Conference?

Aerie Pharmaceuticals will present at the 20th Annual Needham Virtual Healthcare Conference on April 14, 2021, at 12:45 p.m. ET.

Who will present Aerie Pharmaceuticals' business update at the conference?

Vicente Anido, Jr., Ph.D., Chairman and CEO of Aerie Pharmaceuticals, will present the business update.

How can I watch the Aerie Pharmaceuticals presentation?

The presentation will be webcast live and can be accessed on Aerie's website.

What are Aerie Pharmaceuticals' main products?

Aerie's main products include Rhopressa® and Rocklatan®, both aimed at reducing intraocular pressure in patients with glaucoma.

How long will the replay of Aerie's presentation be available?

A replay of the presentation will be available for 10 business days after the event.